Be Careful With Bifurcated Biotech

This column was originally published on RealMoney on Feb. 5 at 12:07 p.m. EST. It's being republished as a bonus for TheStreet.com readers. For more information about subscribing to RealMoney, please click here.

Biotech stocks perked up considerably at the start of January, pointing to a long-overdue rotation into the speculative sector. I looked at this promising development as it unfolded, noting mixed signals among the group's highest-capitalized stocks.

Let's re-examine these top players today and see how their charts are shaping up. ...